Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing
Abstract
Alternative RNA splicing and the spliceosome machinery have been implicated in cancer progression. A genome-wide CRISPR screen identified the RNA processing factor heterogeneous nuclear ribonucleoprotein L (HNRNPL) as required for prostate cancer growth by regulating alternative RNA splicing and circular RNA formation. HNRNPL and its RNA clients are overexpressed during prostate cancer progression, supporting their potential role as therapeutic targets.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 13, 2017
- Source ID
- 10.1073/pnas.1617467114
Entities
People
- Felix Y. Feng
- Housheng Hansen He
- Laura Cato
- Massimo Loda
- Maura B. Cotter
- Michaela Bowden
- Myles A. Brown
- Peng Zhang
- Qiu Wu
- Rosina T Lis
- Shuang G. Zhao
- Teng Fei
- Tengfei Xiao
- Wei Li
- Xiaole Shirley Liu
- Yiwen Chen
Organizations
- Broad Institute
- Dana–Farber Cancer Institute
- Harvard Medical School
- Harvard T.H. Chan School of Public Health
- National Cancer Institute
- Northeastern University
- Tongji University
- United States Department of Defense
- University of Michigan
- University of Texas at Austin
- University of Toronto